GSK has paid out $9.1 billion since 2003
GlaxoSmithKline (GSK) is in the news again making headlines after having to settle another major lawsuit bringing the latest total to over $9.1 billion since 2003. This time, it is due to GSK’s product Pandemrix, which was the swine flu vaccine forced upon the public during the pandemic of 2009 (which is argued by some to have been fake). As the victims are being compensated in the U.K., the same neurological mechanisms that damaged the children in the lawsuit are still potentially at work in the confirmed excitotoxicity that takes place after many vaccine injections.
According to the International Business Times U.K. Edition, each of the victims is “expected to receive £1 million each.” Peter Todd, a lawyer who represented many of the claimants, told the Sunday Times (U.K.):
“There has never been a case like this before. The victims of this vaccine have an incurable and lifelong condition and will require extensive medication.”
Unfortunately for Peter Todd and the countless other victims, there has been cases like this before. Neurological damage from vaccines is not a rare occurrence. In fact, the U.S. government has paid out $3 billion and counting to families of vaccine-injured children. Most of which were due to direct neurological damage or complications arising from such damage.
According to The Global Research Project, the GlaxoSmithKline rap sheet states:
“In recent years, GlaxoSmithKline has become known as the company that pays massive amounts to resolve wide-ranging charges brought by U.S. regulators and prosecutors.
These included a $750 million payment relating to the sale of adulterated products from a facility in Puerto Rico and a record $3 billion in connection with charges relating to illegal marketing, suppression of adverse safety research results and overcharging government customers. The company also set a record for the largest tax avoidance settlement with the U.S. Internal Revenue Service.”
If GlaxoSmithKline wasn’t afforded legal and financial government protection status, they would have went under years ago. However, this corporate zombie still damages populations with little oversight and deep pockets to pay for any legal or ethical challenges that get in the way.
Currently, GlaxoSmithKline, Merck, and other pharmaceutical houses were influential in the passing of California Senate Bill 277 to remove the “parental opposition” that was slowing their product’s revenue stream. What wasn’t disclosed during the senate hearing, or vote following, was that the bill’s author Richard Pan had financial ties to GlaxoSmithKline and Merck. In a fair legal system, this should immediately disqualify the bill and bring serious moral and ethical challenges to Pan’s legitimacy.